Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New cholesterol-lowering ingredient

This article was originally published in The Tan Sheet

Executive Summary

Next Pharmaceuticals announces Dec. 5 its patented heart-health ingredient Flavoxine is clinically shown to increase HDL-cholesterol while "significantly reducing" LDL-cholesterol and triglycerides. The double-blind, placebo-controlled clinical trial included 80 subjects. "The active compounds from the plants used have been studied extensively and therefore Flavoxine does not have the risks frequently associated with new synthetic compounds," says Next Pharmaceuticals President and CEO Bob Garrison. The Carlsbad, Calif.-based company says Flavoxine is a blend of a proprietary extract of Phellodendron amurense and a patented extract of orange peel containing polymethoxylated flavones. The firm says the ingredient will be available to consumer product manufacturers in January...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS100032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel